ProCE Banner Activity

What a (Somewhat) Strange Trip It’s Been: DTG in Women of Childbearing Potential

Clinical Thought
Once perceived as unsafe, during the past 3 years, dolutegravir (DTG) has shifted to being recommended as first-line treatment in women trying to conceive and in those who are pregnant. Read my take on the evolution of our use of DTG in women of child-bearing potential.

Released: November 18, 2021

Expiration: November 17, 2022

Share

Faculty

Joseph J. Eron

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare

Faculty Disclosure

Primary Author

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Joseph J. Eron, Jr., MD, has disclosed that he has received funds for research support from Gilead Sciences, Janssen, and ViiV Healthcare; and has received consulting fees from Gilead Sciences, Janssen, Merk, Trio Health, and ViiV Healthcare.